Several systemic therapy options are available for advanced renal cell carcinoma (aRCC). Preference for a drug depends notonly on the efficacy but as well on other attributes, such as adverse events and the administration method. Thus, it can beexpected that the preferences of health care professionals would have an impact on the successful treatment of disease.
